Oriva Therapeutics, backed by Asabys Partners, is preparing to develop innovative treatments for chronic women's diseases, leveraging advanced assets from its parent companies.

Target Information

Oriva Therapeutics is a newly established biotechnology company focused on developing innovative treatments for prevalent chronic diseases affecting women, such as endometriosis and uterine fibroids. This company has integrated two advanced assets originating from its parent companies, Oncostellae and Medibiofarma, which have been financially supported by Sodena since 2013 and 2019, respectively. As one of the first clinical-stage biotechnology companies in Spain, Oriva aims to exclusively target gynecological conditions with groundbreaking therapies.

The initial asset, ORV-362, is a non-hormonal therapy with disease-modifying capabilities for treating endometriosis, a condition affecting approximately 10% of women and girls of reproductive age globally. ORV-362 is designed to be compatible with conception and has demonstrated a favorable safety profile in clinical trials conducted by the originating company. The program is moving into Phase I trials with healthy women in January 2026. The second asset, ORV-499, targets the treatment of uterine fibroids, the most common benign gynecological tumors, with expectations to initiate Phase I clinical trials in the first quarter of 2027. Both assets are based on validated therapeutic targets and utilize innovative chemistry that distinguishes them from existing market options.

Industry Overview

The biotechnology industry in Spain has seen remarkable growth in recent years, driven by advancements in research and the increasing demand for innovative healthcare solutions. Spain is recognized as one of the leading countries in the European biotechn